<?xml version="1.0" encoding="UTF-8"?>
<ref id="B52-ijerph-17-00440">
 <label>52.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zeuzem</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Foster</surname>
    <given-names>G.R.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Asatryan</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Gane</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Feld</surname>
    <given-names>J.J.</given-names>
   </name>
   <name>
    <surname>Asselah</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Bourliere</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Ruane</surname>
    <given-names>P.J.</given-names>
   </name>
   <name>
    <surname>Wedemeyer</surname>
    <given-names>H.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection</article-title>
  <source>N. Engl. J. Med.</source>
  <year>2018</year>
  <volume>378</volume>
  <fpage>354</fpage>
  <lpage>369</lpage>
  <pub-id pub-id-type="doi">10.1056/NEJMoa1702417</pub-id>
  <?supplied-pmid 29365309?>
  <pub-id pub-id-type="pmid">29365309</pub-id>
 </element-citation>
</ref>
